Emcure Pharmaceuticals Limited, a prominent player in the Indian pharmaceutical sector, is aiming to cater to a growing dermatology segment in India by forming a wholly-owned subsidiary, Emcutix Biopharmaceuticals Limited. This strategic move aims to enhance Emcure’s existing dermatology operations and meet the growing demands of the Indian market.
The focus will be on building a differentiated product portfolio, including first-time launches targeted to meet the unmet requirements of the Indian dermatology market.
With a dedicated team and a renewed focus, Emcutix is set to develop a diverse range of innovative products tailored to address the unmet needs of Indian consumers. The Indian dermatology market, valued at $1.84 billion as of July 2024 according to IQVIA, is experiencing significant growth driven by an expanding population and increasing consumer awareness about skin health.
